Recursion Pharmaceuticals, Inc. - Class A (RXRX) is listed on NASDAQ in Biotech Stocks. It is $3.33, -3.20%, with a $1.8B market cap. RSI is 53.9, neutral. The latest reported quarter missed estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 53.9 Neutral
Market Cap $1.8B
Volume 7.4M
Fundamentals — 10-Q Q2 2026
Revenue $14.1M
Net Income $-248.5M
EPS $-0.47
Gross Margin -69.6%
Operating Margin -1862.9%
Net Margin -1757.1%
P/E Ratio -7.1x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Borgeson Blake | Director | Sell | 30,000 | $3.25 | $97,500 | 2026 Aug 4 |
| Borgeson Blake | Director | Sell | 40,000 | $3.96 | $158,500 | 2026 Jul 7 |
| Bumpus Namandje | Director | Sell | 3,963 | $3.18 | $12,602 | 2026 Jun 18 |
| Gibson Christopher | Director | Sell | 40,000 | $3.62 | $144,800 | 2026 Jun 5 |
| Khan Najat | CEO and President | Sell | 23,588 | $3.58 | $84,459 | 2026 Jun 5 |
| Bumpus Namandje | Director | Sell | 4,386 | $3.54 | $15,526 | 2026 Jun 3 |
| Borgeson Blake | Director | Sell | 30,000 | $3.68 | $110,400 | 2026 Jun 2 |
| Gibson Christopher | Director | Sell | 40,000 | $3.08 | $123,200 | 2026 May 22 |
| Gibson Christopher | Director | Sell | 40,000 | $3.37 | $134,800 | 2026 May 7 |
| Borgeson Blake | Director | Sell | 30,000 | $3.52 | $105,600 | 2026 May 5 |
| Gibson Christopher | Director | Sell | 40,000 | $3.61 | $144,400 | 2026 Apr 22 |
| Gibson Christopher | Director | Sell | 40,000 | $3.10 | $124,000 | 2026 Apr 7 |
| Borgeson Blake | Director | Sell | 30,000 | $3.10 | $93,000 | 2026 Apr 7 |
| Gibson Christopher | Director | Sell | 40,000 | $3.25 | $130,000 | 2026 Mar 23 |
| Taylor Ben R | Chief Financial Officer | Sell | 7,956 | $3.39 | $26,971 | 2026 Mar 17 |
| Khan Najat | CEO and President | Sell | 28,298 | $3.35 | $94,660 | 2026 Mar 9 |
| Borgeson Blake | Director | Sell | 170,000 | $3.46 | $588,200 | 2026 Mar 3 |
| Taylor Ben R | Chief Financial Officer | Sell | 21,383 | $4.18 | $89,381 | 2025 Dec 29 |
| Khan Najat | Chief R&D Commercial Officer | Sell | 124,403 | $4.41 | $548,617 | 2025 Dec 22 |
| Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.50 | $180,000 | 2025 Dec 19 |
Other Biotech Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $137.93 | 63.6 | $55.1B |
| | $432.33 | 66.2 | $233.7B |
| | $145.64 | 60.3 | $180.6B |
Take RXRX further
- Browse Biotech Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put RXRX in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Recursion Pharmaceuticals, Inc. - Class A next reports.
Set alerts on RXRX
Get notified when Recursion Pharmaceuticals, Inc. - Class A hits your price targets or technical conditions are met.
Get Started Free